Bio-Rad Announces FDA Clearance Of Its Bioplex 2200 Syphilis Total & RPR Assay, A Novel Syphilis Testing Method

HERCULES, CA--(Marketwired - June 12, 2017) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, today announced it has received U.S. Food and Drug Administration (FDA) clearance for its BioPlex® 2200 Syphilis Total & RPR assay, a novel one-step universal testing method to aid in the diagnosis of syphilis infection.

The BioPlex 2200 Syphilis Total & RPR (rapid plasma reagin) assay offers laboratories the first fully automated Treponemal/non-Treponemal dual assay, which simultaneously detects antibodies to T. pallidum and reagin antibodies as well as RPR titer (the level of antibody) determination for effective treatment monitoring. Compared to traditional manual RPR card tests, the automation of RPR testing offers labor savings, objective result reporting, and improved workflow to laboratories.

“The addition of the BioPlex 2200 Syphilis Total & RPR assay broadens our expanding BioPlex 2200 System infectious disease menu while offering laboratories a simplified approach to syphilis testing, and it is adaptable to any testing algorithm used by a laboratory,” said John Hertia, Bio-Rad President, Clinical Diagnostics Group.

The release of the BioPlex 2200 Syphilis Total & RPR assay is the latest offering in Bio-Rad’s growing infectious disease menu for the BioPlex® 2200 System, a fully automated multiplex technology platform. The BioPlex 2200 System provides clinical laboratories the capability to rapidly process or “multiplex” multiple individual tests that are traditionally processed separately, conserving patient sample volume and simplifying workflow.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The Company employs more than 8,350 people worldwide and had revenues exceeding $2 billion in 2016. For more information, please visit www.bio-rad.com.

Bio-Rad Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding plans to introduce new products and the opportunities that may result from such new products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “offers,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.